|
業務類別
|
Biotechnology |
|
業務概覽
|
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998. |
| 公司地址
| 321 Arsenal Street, Suite 101, Watertown, MA, USA, 02472 |
| 電話號碼
| +1 617 674-9274 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.discmedicine.com |
| 員工數量
| 155 |
| Ms. Pamela Stephenson |
Chief Commercial Officer |
美元 520.00K |
28/04/2026 |
| Dr. John D. Quisel, J.D.,PhD |
Director, President and Chief Executive Officer |
美元 695.00K |
28/04/2026 |
| Dr. William Savage, M.D.,PhD |
Chief Medical Officer |
美元 523.00K |
28/04/2026 |
| Mr. Jonathan Yu, M.B.A. |
Chief Operating Officer |
美元 507.00K |
28/04/2026 |
| Ms. Jean M. Franchi |
Principal Accounting Officer and Chief Financial Officer |
美元 531.00K |
28/04/2026 |
| Mr. Rahul Khara, J.D.,Pharm.D. |
Chief Legal Officer |
-- |
28/04/2026 |
|
|
| Dr. Kevin Bitterman, PhD |
Independent Director |
28/04/2026 |
| Mr. Mark Chin, M.B.A.,M.S. |
Independent Director |
28/04/2026 |
| Mr. William R. White, J.D. |
Independent Director |
28/04/2026 |
| Dr. John D. Quisel, J.D.,PhD |
Director, President and Chief Executive Officer |
28/04/2026 |
| Dr. Donald W. Nicholson, PhD |
Executive Chairman of the Board |
28/04/2026 |
| Dr. Liam Ratcliffe, M.B.,M.B.A.,PhD |
Independent Director |
28/04/2026 |
| Mr. Nadim Ahmed |
Director |
28/04/2026 |
| Dr. Georges Gemayel,PhD |
Independent Director |
28/04/2026 |
|
|
|
|
